Cardiovascular benefits of statin plus ezetimibe combination therapy versus statin monotherapy in acute coronary syndrome: a meta-analysis of randomized controlled trials

BACKGROUND: The efficacy of adding ezetimibe to statin therapy for event reduction in patients with acute coronary syndromes (ACS) remains a topic of ongoing debate. METHODS: We performed a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing ezetimibe plus statin versus statin monotherapy in patients with ACS. We searched PubMed, Embase, and Cochrane for eligible trials. The random-effects model was used to calculate the risk ratios with 95% confidence intervals (CIs). Statistical analyses were performed using RStudio version 4.2.3 (RStudio, PBC). RESULTS: Six RCTs comprising 20 574 patients with ACS were included, of whom 10 259 (49.9%) were prescribed ezetimibe plus statin. The patient population had an average age of 63.8 years, and 75.1% were male. Compared with statin monotherapy, ezetimibe plus statin significantly reduced major adverse cardiovascular events (MACE) (risk ratio 0.93; 95% CI 0.90-0.97; P < 0.01) and nonfatal myocardial infarction (risk ratio 0.88; 95% CI 0.81-0.95; P < 0.01). There was no significant difference between groups for revascularization (risk ratio 0.94; 95% CI 0.90-1.00; P = 0.03), all-cause mortality (risk ratio 0.87; 95% CI 0.63-1.21; P = 0.42), or unstable angina (risk ratio 1.05; 95% CI 0.86-1.27; P = 0.64). CONCLUSION: In this meta-analysis of patients with ACS, the combination of ezetimibe plus statin was associated with a reduction in MACE and nonfatal myocardial infarction, compared with statin monotherapy.

Estratégias de segurança nos procedimentos da hemodinâmica / Safety strategies in hemodynamic procedures

INTRODUÇÃO: A segurança do paciente é uma prioridade na assistência à saúde, visando minimizar o risco de danos desnecessários. A Organização Mundial da Saúde (OMS) desenvolveu a Classificação Internacional de Segurança do Paciente para fornecer diretrizes, estratégias e recomendações. A Seção de Cardiologia Intervencionista realiza procedimentos diagnósticos e terapêuticos complexos, com abordagem minimamente invasiva. A equipe de enfermagem desempenha um papel crucial em todas as etapas do cuidado ao paciente, desde preparo do paciente pré, trans e pós procedimento na sala de recuperação pós anestésica da Hemodinâmica. O enfermeiro atua no gerenciamento de recursos humanos e materiais, atividades assistenciais e implementação de processos relacionados à qualidade e segurança. A Instituição Pública Especializada em Cardiologia, busca certificação de Acreditação Hospitalar, implementando práticas alinhadas com metas internacionais de segurança do paciente. OBJETIVO(s): Descrever a implementação de estratégias de segurança do paciente incorporadas em um serviço de hemodinâmica. MÉTODOS: Estudo observacional, descritivo sobre processos implementados para segurança do paciente em um serviço de hemodinâmica. Realizado em uma instituição de grande porte especializada em Cardiologia do município de São Paulo. Para a implementação de estratégias seguiram-se as metas internacionais de segurança do paciente. RESULTADOS: Identificou-se das estratégias implementadas para segurança do paciente em procedimento intervencionista hemodinâmico - Conferência de Identificação do paciente com Prontuário Eletrônico; o uso do SBAR (Situação, Contexto, Avaliação e Recomendação): como Ferramenta desenvolvida para transição de cuidado e melhora da Comunicação: a Dupla Checagem de medicamentos de alta vigilância eficiente para melhora da segurança dos medicamentos; Implementação de checklist cirúrgico adaptado para a Hemodinâmica (início fevereiro de 2024); Práticas de Promoção e Prevenção de controle das infecções como práticas assépticas, a sensibilização do uso da higienização das mãos e barreiras adotadas para Prevenção de Quedas. CONCLUSÃO: As estratégias aplicadas por toda equipe multiprofissional, reduzem os riscos de danos ao paciente, promovendo uma cultura de segurança e melhorando a qualidade dos serviços prestados.

Net benefit of closure of patent forame oval in reduction of stroke rates: update meta analisys with randomized controlled trial and observational cohorts with propensity score matched studies

BACKGROUND: Cryptogenic strokes, accounting for 40% of acute ischemic strokes, are linked to patent foramen ovale (PFO). Despite research efforts, uncertainties remain about optimal prevention strategies. OBJECTIVES: Therefore, we aimed to review RCTs and Propensity Score Matching (PSM) Studies comparing percutaneous transcatheter closure (PTC) versus drug treatment in patients with PFO. METHODS: We searched PubMed, Embase and Cochrane. Outcomes: stroke, transient ischemic attack (TIA), all-cause-mortality, AF and major bleeding. We performed subgroup analyses according to the shunt size and age for stroke endpoint. Statistical analysis was performed using the R program (version 4.3.2). Heterogeneity was assessed with I2 statistics. RESULTS: We included 6 RCTs and 7 PSM studies with 13072, of whom 56% underwent PTC. Mean follow-up ranged from 2 to 9 years. In PTC group there was a significant decreased stroke (HR 0.59; 95% CI 0.37-0.95; p<0.0001; I²=72%), major bleeding (OR 0.66; 95% CI 0.49-0.90; p=0.007; I²=28%) and all-cause mortality (OR 0.51; 95% CI 0.39-0.66; p<0.01; I²=0%). The PTC approach was associated with fewer stroke events in patient subgroups with moderate to large shunt size (HR 0.30; 95% CI 0.18-0.50; p<0.001 ; I²=0%) and patients aged between 18 and 45 years old (HR 0.29; 95% CI 0.15-0.56; p<0.001 ; I²=0%). There was an increase of AF (OR 3.16; 95% CI 1.58-6.33; p=0.001; I²=65%). No statistical significance was found in TIA (HR 0.77;95% CI 0.54-1.11; p=0.16; I²=54%). CONCLUSION: In this meta-analysis of RCTs and PSM observational studies of patients with PFO, PTC was associated with lower risk of all-cause mortality and stroke and increased risk of onset AF.

Comparação entre métodos de fisiologia invasiva e não invasiva em um hospital terciário do SUS / Comparison between invasive and non-invasive physiology methods in a SUS tertiary hospital

INTRODUÇÃO: A doença arterial coronariana é altamente prevalente e maior causa de morte no Brasil e no mundo, além de impactar na qualidade de vida dos pacientes e nos custos à saúde. Muitos pacientes submetidos a coronariografia observam-se lesões moderadas (estenose entre 50%-70%), sua correta interpretação, associado a outros métodos diagnósticos é imperativa, visto que mesmo lesões consideradas não graves (< 70%) podem gerar isquemia, agravar sintomas e aumentar a morbimortalidade dos pacientes. A fisiologia invasiva (hiperêmica ou não hiperêmica) é o padrão ouro para avaliar essas lesões encontradas, porém, esta é uma tecnologia subutilizada nos laboratórios de hemodinâmica pela necessidade de hiperemia, aumento do tempo de procedimento, aumento da quantidade de contraste utilizado, dose de radiação e custos. Em contrapartida, avaliação fisiológica baseado na angiografia (sem a necessidade de fio guia pressórico - QFR) ganha espaço, já amplamente corroborado por evidências científicas de redução de desfechos. OBJETIVO(s): Comparar a avaliação de fisiologia invasiva (FFR ou RFR) e não invasiva (QFR) em pacientes de um hospital público terciário, para análise de concordância entre os métodos e possíveis fatores que aumentem a chance de não concordância entre os resultados, visando melhor planejamento terapêutico e redução de custos para a saúde pública. MÉTODOS: Foram levantados prontuários de 123 pacientes submetidos a avaliação de fisiologia invasiva no período de fevereiro de 2022 a março de 2024, buscando a prevalência de comorbidades (hipertensão arterial, diabetes, dislipidemia, histórico de tabagismo, infarto e angioplastia prévia), e comparação das meses lesões com fisiologia não invasiva. RESULTADOS: Foi observado 70,5% de HAS, 46% de DM, 9,8% de tabagistas ativos, 32% de ex-tabagistas, e 34,3% de pacientes com histórico de IAM prévio. O vaso analisado foi a DA em 73,5% dos casos, CX em 11,7% e CD em 9,8%. A taxa de concordância observada foi de 75,6% (90/123) entre os resultados de FFR/RFR e QFR. CONCLUSÕES: Esta é uma avaliação parcial dos dados do estudo, que pretende alcançar um n de, pelo menos, 409 pacientes/lesões analisadas. Até o momento não foi possível estabelecer a concordância entre o resultado da fisiologia invasiva e não invasiva. Mesmo este resultado parcial é possível observar que os métodos de avaliação de fisiologia não invasivos são uma ferramenta extra para guiar a melhor terapêutica.

Prevalência de doença coronariana obstrutiva por angiografia de pacientes internados com angina instável em pronto-socorro terciário de cardiologia na era de troponina convencional / Prevalence of obstructive coronary disease by angiography in patients hospitalized with unstable angina in a tertiary cardiology emergency department in the conventional troponin era

INTRODUÇÃO: O manejo da angina instável é marcado por desafios diagnósticos devido à sua natureza subjetiva e limitada representação em ensaios clínicos randomizados. Atualmente, recomenda-se realização da estratégia invasiva direta (cinecoronariografia) somente para pacientes de alto risco, classificados através de escores ou alterações eletrocardiográficas, porém tal recomendação ainda não é validada em uma população de pacientes com múltiplas comorbidades. OBJETIVO: Este estudo visa avaliar o perfil de comorbidades, eletrocardiograma e padrão angiográfico de pacientes internados com angina instável em um pronto-socorro terciário de cardiologia. METODOLOGIA: Coorte retrospectiva, que incluiu pacientes com diagnóstico de angina instável em um período de 20 meses consecutivos, com o uso de troponina convencional. Foram excluídos pacientes que não foram submetidos à cinecoronariografia. Foi realizada análise descritiva das variáveis escolhidas. RESULTADOS: Entre o período de julho de 2018 e fevereiro de 2020, 729 pacientes foram internados com diagnóstico de Angina Instável. Desses, 611 (84%) realizaram cinecoronariografia em algum momento da internação. A idade média desses pacientes foi de 63 anos (±10.6), sendo 36% do sexo feminino, 82% hipertensos, 45% diabéticos tipo 2, 59% dislipidêmicos, 18% tabagistas , 19% doentes renais crônicos e 62% já tinham diagnóstico de doença coronariana prévia. O escores classificaram os pacientes como de risco baixo a moderado, com GRACE médio de 92,5 (±25,6), TIMI 3,4 (±1,5) de e HEART de 5 (±1). Também não houve alterações eletrocardiográficas significativas: apenas 12% tinham alterações isquêmicas de onda T e apenas 2% tinham infradesnivelamento do segmento ST. Das 611 cinecoronariografias realizadas, foram realizados 316 procedimentos de angioplastia (52%), sendo 15% com envolvimento de DA proximal ou TCE. A prevalência de obstrução coronariana foi descrita com mais detalhes na figura 1. CONCLUSÃO: Em pacientes internados por angina instável, análise da angiografia demonstrou alta prevalência de obstrução coronariana em contraste com escores e eletrocardiograma que classificavam a maioria dos pacientes como risco baixo a moderado. Nossos achados sugerem que, em pacientes com alta probabilidade de DAC, como na amostra, solicitar cinecoronariografia como primeiro exame de estratificação nesses doentes pode ser uma estratégia adequada.

HLA-I and breast cancer prognosis: a systematic review and meta-analysis

BACKGROUND: Breast cancer (BC) is a significant global health issue, accounting for 1 in 8 cancer diagnoses worldwide. HLA class I molecules are typically expressed on the cell surface, but cancer cells can develop mechanisms to evade recognition by CTLs, including the downregulation of HLA class I expression. In this context, we aimed to conduct a systematic review and meta-analysis to clarify the role of HLA class I expression in clinical outcomes for patients with BC. METHODS: A comprehensive literature search was conducted across PubMed, Scopus, Web of Science, and the Cochrane databases. Effect sizes, along with I2 and Tau2 statistics, were used to assess heterogeneity through a DerSimonian and Laird random-effects model. Statistical analyses were performed using R statistical software, version 4.2.3. RESULTS: Among the 8 included studies, most of the analyzed samples consisted of ductal carcinoma cases (1588, 86.39 %), from the luminal (A or B) intrinsic subtype (1865, 69.07 %), with no lymph node metastasis (2658, 57.24 %), no HER2 overexpression (2594, 67.46 %), negative Ki67 status (1721, 71.26 %), and positive hormone receptor status (4732, 64.05 %). The analysis revealed a significant reduction in disease-free survival (HR 0.57; 95 % CI 0.34 to 0.95; p = 0.034; I2 = 84 %) in the group with low HLA-I expression. However, no significant difference was found between the groups with high and low HLA-I expression regarding overall survival (HR 0.77; 95 % CI 0.28 to 2.14; p = 0.62; I2 = 86 %). CONCLUSIONS: This systematic review and meta-analysis demonstrated that HLA class I expression is associated with a significant improvement in disease-free survival, though no significant effect on overall survival was observed.

Colesterol não controlado em indivíduos com hipercolesterolemia grave acompanhados em um programa de avaliação da saúde no Brasil / Uncontrolled Cholesterol in Individuals with Severe Hypercholesterolemia in a Health Evaluation Program in Brazil

FUNDAMENTO Indivíduos com hipercolesterolemia grave (HG) são considerados sob alto risco de desenvolverem aterosclerose e devem ser intensivamente tratados com medicamentos hipolipemiantes, visando uma redução nos níveis de LDL-Colesterol ≥50% e uma meta <70 mg/dL. OBJETIVOS Este estudo teve como objetivo avaliar o controle dos níveis de colesterol em indivíduos com HG (LDL-C ≥ 190 mg/dL ou 160-189 mg/dL usando medicamentos hipolipemiantes) acompanhados em um programa de avaliação da saúde. MÉTODOS Foram avaliados 55 000 indivíduos, dos quais 2214 (4%) apresentavam HG, e 1016 (45,8%) foram submetidos a avaliações repetidas. O alcance das metas de LDL-C foi o desfecho primário do estudo. Um valor de p<0,05 foi considerado significativo. RESULTADOS A idade média (±DP) foi 44,9±8,8 anos; 84,2% dos participantes eram do sexo masculino, e 0,5% relataram infarto do miocárdio prévio. A concentração média de LDL-C foi 203,0±22,0 mg/dL, e apesar de 62,5% dos pacientes terem referido dislipidemia, somente 19% estavam usando drogas hipolipemiantes (5,9% nos casos de LDL-C ≥ 190 mg/dL). Durante um seguimento de 4,1±2,8 anos, o uso de medicamentos hipolipemiantes aumentou de 18,1% para 48,4% (p<0,00001); de 5,9% para 45,4% naqueles com LDL-C ≥ 190 mg/dL (p< 0,00001), embora 31% dos casos com LDL-C 160-189 mg/dL terem interrompido o uso desses fármacos. No geral, observou-se uma redução média de 26,7% nos níveis de LDL-C (p<0,0001). Reduções ≥50% no LDL-C foram alcançadas por 19,2%, 19,1%, e 19,7 % de todos os indivíduos, e naqueles com LDL-C > 190 mg/dL e 160-189 mg/dL, respectivamente. Somente 3,1% atingiram concentrações de LDL-C < 70 mg/dL (2,7% naqueles com LDL-C ≥ 190 e 5,3% naqueles com 160-189 mg/dL). CONCLUSÕES Uma séria lacuna foi encontrada entre as recomendações de tratamento e a realidade em indivíduos com elevado risco aterosclerótico por HG.

Cardiomiopatia dilatada: apresentação da mutação genética da FLN-C em paciente jovem candidato a transplante / Dilated cardiomyopathy: presentation of the FLN-C genetic mutation in a young patient who is a candidate for transplant

FUNDAMENTO: A cardiomiopatia dilatada (CMD) é comum, com prevalência de 1/250 a 1/500 na população geral. É a principal causa de transplante cardíaco. Quando sua etiologia não é bem definida a investigação de uma causa genética se faz relevante. Em 40% é encontrada uma variante genética que pode explicar o fenótipo cardíaco encontrado. A prevalência de variantes do'* gene da filamina-C (FLNC) em pacientes com CMD é de até 4,5%. Tais mutações foram inicialmente relacionadas a uma forma de miopatia miofibrilar esquelética associada, em alguns casos, a uma forma não especificada de "cardiomiopatia". Por isso, desde 2012, o FLNC foi incluído na triagem genética de pacientes com cardiomiopatias hereditárias e morte súbita. RELATO DE CASO: Masculino, 15 anos, previamente hígido, deu entrada em pronto-socorro por primo-descompensação de Insuficiência Cardíaca em Perfil C. Relato de apresentar há semanas: fadiga, cansaço e dispneia aos esforços. A progressiva piora dos sintomas o fez buscar a emergência. Histórico familiar de CMD (mãe), com morte súbita aos 40 anos. O fato levantou hipótese para uma possível hereditariedade genética como etiologia à sua condição cardíaca. Ao ecocardiograma mostrou aumento importante das câmaras cardíacas esquerdas, com hipocontratilidade miocárdica difusa (FEVE=18% pelo Simpson). Disfunção Sistólica do Ventrículo Direito (FAC 18%) e sinais de hipertensão pulmonar. Foi realizada uma Ressonância Magnética Cardíaca, que demonstrou presença de realce tardio com morfologia não isquêmica sugerindo um padrão de cardiomiopatia genética. Após tentativas de otimização do tratamento e falhas no desmame do inotrópico, o transplante cardíaco foi considerado como única proposta terapêutica possível. Foi realizado teste genético para cardiomiopatias hereditárias, apresentando a variante patogênica no gene FLNC. Pacientes segue estável e em lista para o Transplante Cardíaco em uso de inotrópico. CONCLUSÃO: A pesquisa genética desempenha um papel importante na busca pela etiologia da Insuficiência Cardíaca presumivelmente idiopática. Especialmente por levar a diagnósticos mais específicos e oferecer um manejo mais adequado ao paciente. Em casos em que as alterações genéticas estejam associadas a um alto risco de morte súbita o implante de CDI pode ser indicado conforme a orientação das últimas diretrizes. Por isso, em pacientes com insuficiência cardíaca idiopática, o teste genético deve ser considerado como parte da investigação diagnóstica. Com finalidade de uma estratificação de risco mais precisa e a implementação de medidas terapêuticas de relevância prognóstica.

Artificially sweetened beverages and cardiovascular events: a meta-analysis of nearly one million cohort patients

BACKGROUND: With the rising use of artificial sweeteners as sugar substitutes, concerns regarding their impact on cardiovascular health have emerged. Despite approval by national food regulatory agencies, evidence of their association with clinically significant cardiovascular events remains inconclusive. This study aimed to assess this relationship through a systematic review and meta-analysis. METHODS: PubMed, Embase, and Cochrane databases were systematically searched for cohort studies investigating the incidence of stroke, cardiovascular death (CVD), coronary heart disease (CHD), and all-cause mortality (ACM) among individuals with high consumption of artificially sweetened beverages (ASBs) compared to minimal or no consumption. Pooled event prevalence and hazard ratios (HR) with 95% confidence intervals (CI) were calculated using a random-effects model in R software, with heterogeneity assessed via I2 statistics. RESULTS: After overlapping population disposal, eight cohorts comprising 917,971 patients (mean age 52 years; 67.7% female) were included. Analyses were conducted on patient groups with data adjusted for dietary factors, comorbidities, and family history of heart disease. High Consumption of ASBs was significantly associated with a higher risk of ACM (HR 1.1760; 95% CI 1.0186-1.3578, p=0,027), stroke (HR 1.2501; 95% CI 1.0555-1.4807, p=0,01) and CVD (HR 1.4722; 95% CI 1.2821-1.6905, p<0,001). There was no statistically significant association found for CHD (HR 1.1215; 95% CI 0.9280-1.3554, p=0,235). CONCLUSION: In this meta-analysis, we found a significant association between high consumption of ASBs and increased incidence of ACM, CVD, and stroke highlighting potential cardiovascular implications. Further studies with improved methodologies are needed to corroborate these findings and elucidate the underlying mechanisms.

Diagnostic accuracy of artificial intelligence-based electrocardiogram algorithm to predict heart failure with reduced ejection fraction: a systematic review and meta-analysis

INTRODUCTION: AI-based EKG has shown good accuracy for diagnosing heart failure. However, due to the heterogeneity of studies regarding cutoff points, its precision for specifically detecting heart failure with reduced ejection fraction (LVEF <40%) is not yet well established. Research question: What it is the sensitivity and specificity of artificial-based electrocardiogram to diagnose heart failure with low ejection fraction(cut-off of 40%) Aims: We conducted a meta-analysis and systematic review to evaluate the accuracy of artificial intelligence electrocardiograms in predicting an ejection fraction below 40%. METHODS: We searched PubMed, Embase and Cochrane Library for studies evaluating the performance of AI EKGs in diagnosing HFrEF. We computed true positives, true negatives, false positives and false negatives events to estimate pooled sensitivity, specificity and area under the curve, using R software version 4.3.1, under a random-effects model. RESULTS: We identified 8 studies,including 136151 patients with a paired artificial intelligence enabled electrocardiogram with an echocardiography. 9349(6.8%) patients had an ejection fraction below 40% according to the echocardiogram. The AI-ECG data yielded areas under the receiver operator of, sensitivity of 0.861(0.815-0.897), and specificity of 0.874(0.834-0.905), and area under the curve of 0.929(0.876-0.949). Mean/median age ranged from 60±9 to 67.8±14.4 years. CONCLUSIONS: In this systematic review and meta-analysis, the use of electrocardiogram-based artificial intelligence models demonstrated high sensitivity and specificity for the diagnosis of heart failure with an ejection fraction below 40%

SGLT2 Inhibitors following acute myocardial infarction: a systematic review and meta-analysis

BACKGROUND: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have demonstrated cardiovascular benefits in various settings. However, their impact after myocardial infarction (MI) in patients without prior heart failure remains unclear. Therefore, we conducted a meta-analysis comparing SGLT2i to placebo in post-MI patients. METHODS: We systematically searched Pubmed, Embase, and Cochrane Central for randomized controlled trials (RCTs) comparing SGLT2i to placebo in post-MI patients. We calculated the Risk Ratio (RR) for binary outcomes and 95% confidence intervals (CI). Statistical analysis was performed using Review Manager 5.4. A random-effects model was used for all outcomes. Heterogeneity was examined with I2 statistics. RESULTS: We included 3 RCTs comprising 11,065 patients in this meta-analysis, where 79.5% were male with a mean age of 61.9 years old. Two studies evaluated Empaglifozin and one Dapagliflozin. There was no statistically significant difference between groups in all-cause mortality (RR 1.05; 95% CI 0.78-1.41; p= 0.76; Figure 1A) and cardiovascular mortality (RR 1.04; 95% CI 0.84-1.29; p= 0.73; Figure 1B). There was a statistically significant reduction in the incidence of heart failure hospitalization in the SGLT2i group (RR 0.73; 95% CI 0.61-0.88; p< 0.01; Figure 1C). CONCLUSION: Our systematic review and meta-analysis found that SGLT2i significantly reduced the incidence of heart failure hospitalization in patients following MI, without significantly affecting all-cause or cardiovascular mortality.

DOACs versus aspirin for secondary prevention of stroke after ESUS: an updated systematic review and meta-analysis of randomized clinical trials

BACKGROUND: Embolic stroke of undetermined source (ESUS) is a nonlacunar ischemic stroke with no clear cause, having a 4%-5% annual recurrence rate. The potential benefits of direct oral anticoagulants (DOACs) relative to aspirin in patients with ESUS remain unclear. OBJECTIVE: We aimed to perform a systematic review and meta-analysis to determine the efficacy of the DOACs in secondary prevention for patients with ESUS compared with aspirin. METHODS: MEDLINE, Embase, Cochrane, and ClinicalTrias.gov were searched for RCTs comparing DOACs versus aspirin for secondary stroke prevention after ESUS. We performed a systematic review and meta-analysis following the Preferred Reporting Items for Systematic Review (PRISMA) and Cochrane guidelines. Statistical analysis was performed using R software 4.3.2. A random-effects model was employed to measure mean differences and hazard ratios (HR) with 95% confidence intervals (CI). RESULTS: We included 4 RCTs comprising 13,970 patients. The median age was 67 years (IQR 65.5-68.2), 61% were male, 76% had hypertension, and 51% had diabetes. DOACs were administered to 50% of the participants. No significant difference was found between groups for stroke recurrence [RR 0.95 (95% CI 0.8-1.11) p=0.52; I2=0%]. Death from any cause [HR 1.11 (95% CI 0.87-1.42) p=0.38; I2=0%], cardiovascular death [HR 1.08 (95% CI 0.61-1.94) p=0.77; I2=18%] and myocardial infarction [HR 0.92 (95% CI 0.54-1.54) p=0.76; I2=16%] were also similar between groups. However, there was a significant increase in clinically relevant non-major bleeding for patients treated with DOACs [HR 1.53 (95% CI 1.22-1.92) p<0.001; I2=9%]. CONCLUSION: In patients with ESUS, DOACs were not superior to aspirin for the secondary prevention of stroke. However, there was a significant increase in clinically relevant non-major bleeding among patients treated with DOACs. These findings suggest that aspirin remains a viable option for secondary prevention in ESUS patients.

Hybrid epicardial and endocardial ablation versus endocardial ablation in patients with persistent and longstanding persistent atrial fibrillation: an updated systematic review and meta-analysis

BACKGROUND: Some studies suggest a potential benefit of hybrid ablation for patients with persistent and long-standing persistent atrial fibrillation (AF), but its efficacy and safety remain debated. OBJECTIVE: We conducted a systematic review and meta-analysis to compare the efficacy and safety of hybrid ablation and catheter ablation in patients with persistent AF and long-standing persistent AF. METHODS: We searched PubMed, Embase and Cochrane Central. Outcomes were the composite endpoints of freedom from atrial arrhythmias, major adverse events, total procedural time, and fluoroscopy time. Statistical analysis was performed using the R program (version 4.3.2). Heterogeneity was assessed with I2 statistics. RESULTS: We included 961 patients from 7 studies. Of those, 4 were RCTs and 3 were observational studies with propensity score matched cohorts. A total of 446 (46.41%) patients received hybrid ablation and 515 (53.59%) received only endocardial. Among the patients included in the study, 674 (70.14%) had persistent AF, and 287 (29.86%) had LSPAF. Moreover, the average atrial diameter was 4.43 cm, and the average duration since AF diagnosis was 3.06 years. Additionally, the average age of the patients was 61.7, and the number of male patients included was 911 (94.80%). The median follow-up ranged from 12 to 43.9 months. Compared to catheter ablation, hybrid ablation was associated with a higher odds of freedom from atrial arrhythmias off antiarrhythmic drugs (OR 3.25; 95% CI 2.08-5.06; p<0.001; I2 = 85%; Figure 1A), and freedom from AF (OR 3.51; 95% CI 1.07 - 11.48; P=0.038; I2=84%; Figure 1B). There were no differences in major adverse events (p=0.98; Figure 1C), total procedure time (p=0.05; Figure 2A), or fluoroscopy time (p=0.85; Figure 2C) between hybrid ablation and catheter ablation. CONCLUSION: This meta-analysis shows hybrid ablation increases the likelihood of maintaining freedom from atrial arrhythmias in patients with persistent and long-standing persistent AF, compared to catheter ablation, without compromising safety.

Sexual minorities cardiovascular health disparities compared to heterosexual adults in the US: a systematic review and meta-analysis of nearly 2 million cohort patients

BACKGROUND: Cardiovascular disease (CVD) remains a leading cause of death globally, yet disparities in CVD outcomes among sexual minorities compared to heterosexual adults are under-researched. Sexual minorities face unique stressors, discrimination, and barriers to healthcare, which may contribute to higher CVD risk. This meta-analysis synthesizes evidence on health disparities between sexual minorities and heterosexual adults. METHODS: We searched MEDLINE, Cochrane, and Embase databases for studies published between 2002 to 2024 that compared cardiovascular health disparities between sexual minorities and their heterosexual counterparts. Outcomes were CVD, Diabetes, Hypertension, and Obesity. We pooled odds ratios (OR) for binary endpoints with 95% confidence intervals (CI) using a random-effects model. Statistical analyses were performed using R software version 4.3.2. RESULTS: We included 9 Cross-sectional studies after minimizing population overlap, comprising 1,938,814 patients with a mean age of 47 years. There were no significant differences in the odds of CVD (OR 1.10; 95% CI 0.87 to 1.39; Figure 1 A), Diabetes (OR 0.88; 95% CI 0.74 to 1.04; Figure 1 B), hypertension (OR 1.07; 95% CI 0.97 to 1.19; Figure 2 A) and Obesity (OR 1.01; 95% CI 0.76 to 1.35; Figure 2 B) between groups. In subgroup analysis, there were higher odds of obesity in the sexual minority population when compared to their heterosexual counterparts (OR 1.29; 95 % CI 1.15 to 1.45) and higher hypertension odds in sexual minority men (OR 1.35; 95% CI 1.12 to 1.63). CONCLUSION: In this meta-analysis, we found no statistically significant difference in the prevalence of CVD, diabetes, and obesity between sexual minorities and heterosexuals, meaning that more studies are necessary to assess this difference. Subgroup analyses revealed sexual minority men had higher odds of hypertension and sexual minority women for obesity.

Dexmedetomidine for junctional ectopic tachycardia in patients undergoing tetralogy of fallot repair: a meta-analysis of randomized controlled trials

BACKGROUND: Junctional ectopic tachycardia (JET) occurs in 2 to 22% of patients after cardiac surgery for congenital heart diseases, including tetralogy of Fallot (TOF) repair. Dexmedetomidine emerged as a potential drug to prevent JET in these patients. This systematic review and meta-analysis aimed to evaluate the efficacy of dexmedetomidine in JET in patients undergoing TOF repair. METHODS: We systematically searched PubMed, Embase, and Cochrane databases for randomized controlled trials (RCTs) analyzing the use of dexmedetomidine in patients undergoing TOF repair. We pooled risk ratios (RR) for binary outcomes, and mean differences (MD) for continuous outcomes with 95% confidence intervals (CI) with a random-effects model. We performed a trial sequential analysis (TSA) to assess the random risk of incidence of JET. We used R version 4.3.2 and TSA version 0.5.9.10 for statistical analyses. RESULTS: Our meta-analysis included 5 RCTs comprising 546 patients, of whom 268 (49%) were randomized to dexmedetomidine. Compared with control, dexmedetomidine significantly reduced the incidence of JET (RR 0.46; 95% CI: 0.30 to 0.71; p<0.05; Figure A). However, there were no significant differences in mortality (RR 0.45; 95% CI: 0.12 to 1.71; p=0.24; Figure B) between groups. In addition, dexmedetomidine also reduced the length of intensive care unit (ICU) stay (MD -7.75 hours; 95% CI: -15.08 to -0.41; p<0.05; Figure C). There were no significant differences in ionotropic score (MD -0.97 ug.min/Kg; 95 % CI: -1.98 to 0.18; p=0.10; Figure D), and ventilation time (MD -2.29 hours; 95% CI: -8.39 to 2.41; p=0.27; Figure E). For the primary endpoint, TSA suggested a low risk of type 1 error; therefore, this result may be conclusive. CONCLUSION: In patients undergoing TOF repair surgery, dexmedetomidine significantly reduced the incidence of JET and the length of ICU stay.

Catheter ablation approach and outcome in HIV+ patients with atrial fibrillation: a systematic review and meta-analysis

BACKGROUND: Catheter ablation has emerged as an effective treatment option for atrial fibrillation (AF) in the general population. However, limited data exist on the outcomes of catheter ablation in patients infected with the Human Immunodeficiency Virus (HIV+) with concomitant AF. OBJECTIVES: This systematic review and single arm meta-analysis aims to comprehensively evaluate the literature on catheter ablation approach and outcome in HIV+ patients with AF. METHODS: A systematic search of PubMed, Embase, and Cochrane Central Register of Controlled Trials was conducted following PRISMA guidelines.Studies meeting the intervention of catheter ablation for AF in HIV+ patients, using radiofrequency, cryoballoon, or pulsed field ablation techniques, were included and data were collected and synthesized using proportion meta-analysis techniques. Statistical analysis was carried out using R software. RESULTS: Three studies met the inclusion criteria, involving 89 HIV+ patients, with an average age of 51.5 years, of whom 83.1% were men, undergoing catheter ablation. Two studies performed received isolation of the pulmonary vein (PV) + posterior wall and superior vena cava. And one study evaluated only the isolation of the pulmonary veins. Of these patients, 43.8% had paroxysmal AF and 56.1% had persistent AF. In two studies reporting freedom from atrial arrhythmias, all patients (62) experienced recurrence of atrial arrhythmias within 5 years of follow-up. Freedom from repeat ablation was 6.26% (Figure 1A). The rate of Pulmonary Vein Trigger was 31.28% (Figure 1B), while the rate of Non-Pulmonary Vein Trigger (non-PV) was 76.64% (Figure 1C). CONCLUSION: In this systematic review and meta-analysis assessing outcomes of ablation in HIV patients with AF, we observed a similar prevalence of paroxysmal and persistent AF. Furthermore, contrary to the non-HIV+ patients, a high incidence of non-pulmonary vein triggers of AF was noted in this population.

Atorvastatin therapy for prevention of anthracycline-induced cardiotoxicity in cancer patients: a meta-analysis

INTRODUCTION: Cancer therapy-induced cardiac dysfunction is a significant adverse effect of chemotherapeutic agents, particularly anthracyclines (ANT). High-potency statin therapy, such as atorvastatin, appears to exert a protective effect against this condition. OBJECTIVE: We aimed to perform a meta-analysis to evaluate the effect of atorvastatin therapy in preventing anthracycline-induced cardiotoxicity in cancer patients. METHODS: We searched PubMed and Web of Science for randomized controlled trial (RCT) studies comparing atorvastatin prophylactic use to placebo in patients with cancer undergoing anthracycline-based chemotherapy. Outcomes were: mean change in left ventricular ejection fraction (LVEF), LVEF final, left ventricular end-systolic volume (LVESV), left ventricular end-diastolic volume (LVEDV), LDL-c, cancer treatment related cardiac disease (CTRCD) and heart failure symptoms. A random effects model was used to calculate the risk ratios (RRs) and mean difference (MDs) with 95% confidence intervals. Statistical analysis was performed using the R program (version 4.3.2). Heterogeneity was assessed with I2 statistics. RESULTS: Five RCTs with 831 participants were included. The median follow-up ranged from 1 to 24 months. The dose used in all studies was 40 mg. Breast cancer was present in 77% of the patients. In our analysis, atorvastatin prophylactic use was associated with a statistically significant lower LVEF final (MD 2.31 %; 95% IC [0,78; 3,84]; p<0.01; I2 =65%), LVESV (MD -4.50 mL; 95% IC [-7,57; -1,44]; p<0.01; I2 =0%), LVEDV (MD -6.08 mL; 95% IC [-11,27; -0,90]; p=0.02; I2 =0%), LDL-c (MD -38.11 mg/dL; 95% IC [-55,01; -21,20]; p<0.01; I2 =89%) and CTRCD (RR 0.42; 95% CI 0.28 - 0.65; p<0.001; I2 =0%). In addition, atorvastatin prophylactic use was associated with a statistically significant increased LVEF final (MD 2.31 %; 95% IC [0,78; 3,84]; p<0.01; I2 = 65%). There was no significant difference between groups in terms of mean change LVEF (MD 2.56 %; 95% IC [-0,20; 5,32]; p=0.07; I2 =89%) and heart failure symptoms (RR 0.40; 95% CI 0.14 - 1.18; p=0.097; I2 =0%). CONCLUSION: In conclusion, atorvastatin prophylactic use to placebo in patients with cancer undergoing anthracycline-based chemotherapy was associated with a reduction in LVESV, LVEDV, CTRCD and an increase in LVEF final. There was no difference between groups regarding mean change LVEF and heart failure symptoms.

Discontinuation vs continuation of renin-angiotensin system inhibition before non-cardiac surgery: a systematic review and meta-analysis

BACKGROUND: The optimal management of angiotensin-converting enzyme (ACE) inhibitors during elective surgeries remains uncertain. While some studies suggest that continuing ACE inhibitors increase the risk of perioperative hypotension, others argue that discontinuation may heighten the risk of significant clinical events. This meta-analysis aims to clarify the clinical outcomes associated with continuation compared to discontinuation of ACE inhibitors in surgical settings. METHODS: We conducted a systematic search of MEDLINE, Cochrane, and Embase for clinical trials comparing the effects of continuing versus discontinuing ACE inhibitors during surgery. Outcomes evaluated included death, stroke, myocardial injury (MI), intraoperative hypotension, postoperative hypotension, and acute kidney injury (AKI). Data were synthesized using odds ratios (OR) with 95% confidence intervals (CI). Heterogeneity was assessed with I2 statistics, and a random-effects model was applied. Statistical analyses were performed using R software version 4.3.2. RESULTS: From 865 identified studies, 15 studies involving 11,519 patients met the inclusion criteria. Not all studies had outcomes available for comparison between them. The average age was 65.75 years, with 86.45% having hypertension and 13.13% with heart failure. Continuing ACE inhibitors was associated with a higher risk of intraoperative hypotension (OR 1.33; 95% CI 1.16-1.53). No significant differences were found between groups for mortality (OR 1.06; 95% CI 0.68-1.65), stroke (OR 0.99; 95% CI 0.47-2.09), MI (OR 0.98; 95% CI 0.72-1.31), postoperative hypotension (OR 1.27; 95% CI 0.74-2.17), and AKI (OR 0.88; 95% CI 0.66-1.16). CONCLUSION: Discontinuation of ACE inhibitors before non-cardiac surgery may lower the risk of intraoperative hypotension without significantly affecting mortality, stroke, MI, postoperative hypotension, or AKI. Further research with greater power and better design is needed to confirm these findings.

Nasal etripamil spray efficacy for acute paroxysmal supraventricular tachycardia: a systematic review, meta-analysis and trial sequential analysis

BACKGROUND: Acute paroxysmal supraventricular tachycardia (PSVT) is a common arrhythmia. Etripamil, a novel calcium channel blocker via nasal spray, has shown promise for PSVT management. This meta-analysis and trial sequential analysis (TSA) evaluates the efficacy and safety of nasal Etripamil for treating PSVT. METHODS: We systematically searched Pubmed, Embase, and Cochrane databases for studies assessing the efficacy and safety of Etripamil for PSVT. The main outcome was conversion to sinus rhythm(CSR) within 15 minutes. Secondary outcomes included adverse events(AE). Meta-analysis was performed using random-effects models, and TSA was employed to assess the robustness of the evidence and required information size. RESULTS: Three randomized controlled trials (RCTs) and two extensive trials involving 1,652 participants were analyzed. Nasal Etripamil significantly increased the CSR within 15 minutes compared to placebo (RR 1.87 95% CI; 1.39-2.52, p <0.001; Figure A). Outcome TSA suggested a low risk of type 1 error; therefore, this result may be conclusive (Figure B). For the AEs both a pairwise and single-arm meta-analysis of studies was performed with 1 AEs being statistically significant in the single-arm plot, Nasal Discomfort (22.11 95% CI; 16.02-29.70 events per 100 observations, p <0.01 Figure C). In the pairwise, the overall was statistically significant and it favored placebo (RR 3.93, 95% CI; 2.46-6.27, p <0.001 Figure D). CONCLUSION: Nasal Etripamil is effective and safe for the treatment of acute PSVT, offering a non-invasive alternative to traditional therapies. Larger-scale RCTs are warranted to confirm these findings and explore long-term outcomes.

The de winter electrocardiographic pattern: a systematic review of case reports

BACKGROUND: It has been established that concurrent ST-T alterations in limb leads can assist in identifying the location of left anterior descending (LAD) artery occlusion. The de Winter pattern is an atypical electrocardiographic manifestation characterized by ST-segment depression associated with LAD artery occlusion. We hypothesized that this atypical pattern could potentially interfere with the accurate localization of the LAD occlusion site on the electrocardiogram. We aimed to describe the distinctive characteristics of the de Winter pattern and to compare electrocardiographic variables in proximal and distal occlusions of the LAD artery. METHODS: A systematic review was conducted using the PRISMA guidelines. PubMed, Scopus, and Web of Science were searched from their inception to June 2024. Continuous variables were compared using the Kruskal-Wallis test. RESULTS: Sixty-six cases with LAD related lesions were included. The majority of cases involved young males with a low proportion of prior coronary artery disease. Most patients had sinus rhythm and normal QRS duration. ST-T changes in limb leads were common in the patients studied (91%), but our analysis showed that differentiating between proximal and distal occlusions based on these changes was challenging. CONCLUSION: The de Winter pattern is primarily observed in young males with a low proportion of prior coronary artery disease. While ST-T changes in limb leads are frequent, localizing the LAD occlusion site based on these changes can be difficult. Further research is needed to understand the underlying mechanisms, prevalence, and improve diagnostic accuracy for this atypical pattern.